Biocon Biologics’ Pebrilzo has become the first biosimilar recommended under the EMA’s tailored clinical approach, offering an early test of how far Europe is prepared to reduce clinical development requirements.
Biocon Biologics’ Pebrilzo has become the first biosimilar recommended under the EMA’s tailored clinical approach, offering an early test of how far Europe is prepared to reduce clinical development requirements.